INDUSTRY INSIGHTS

• Mammalian Cell Line Development

  Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.

• Rapid, Reliable Technology Transfer

  See how structured planning, expert coordination, and risk‑focused execution speed tech transfer, improve consistency, and move biologics into manufacturing faster.

• WuXiHigh 2.0 Delivers A 180 mg/mL Formula

  This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.

• Systematic Strategy To Reduce The Cost Of Goods Sold

  Learn key ways to cut biologics manufacturing costs through smarter process design, material choices, and supply resilience — driving more efficient, reliable, and commercially sustainable production.

• WuXia293Stable: Express What CHO Can't

  Discover a modern 293‑based expression system built for higher purity, controlled glycosylation, and improved activity, offering a new option for teams developing complex or next‑generation biologics.

• WuXiHigh 2.0 In Action

  Explore the growing demand for high‑concentration biologics, and the formulation, viscosity, and manufacturing challenges driving new technologies for stable, scalable drug development.

• Tool Enzymes For Antibody-Drug Conjugate Development And Manufacturing

  See how modern tool enzymes enable cleaner, more consistent ADC conjugation, sharper analytics, and a smoother path from research to clinical development — practical guidance for manufacturing.

• Global Manufacturing Excellence Across Quality, Efficiency, And Cost Of Goods Sold

  Learn strategies to strengthen global biologics manufacturing through consistent quality, advanced technologies, and efficient tech transfer to improve operations and commercial readiness.

• Ensure Successful Viral Clearance

  A decade of viral clearance data comparing established and emerging operations, highlighting LRV performance, key process risks, and practical insights to strengthen downstream safety.

• Deciphering The Complexity Of Therapeutic Biologics

  This session breaks down essential analytical approaches that strengthen biologics development, from defining critical quality attributes to supporting comparability and regulatory readiness.